Amneal Pharmaceuticals (NASDAQ:AMRX) Updates Q1 2026 Earnings Guidance

Key Points

• Q1 guidance and results beat expectations: Amneal issued Q1 2026 EPS guidance of 0.270 and revenue guidance of $723.0M—above consensus (EPS 0.16, revenue $715M)—and reported Q1 EPS of $0.26.
• Strategic acquisition and raised FY outlook: The company agreed to buy Kashiv BioSciences for up to $1.1B to build biosimilars scale and raised FY2026 EPS guidance to $0.95–$1.05 (with revenue guidance of roughly $3.1–$3.2B).
• Profitability and capital-structure risks remain: Despite the beat, Amneal’s net margin is low (~2.4%) and return on equity is deeply negative (~−228%), highlighting ongoing profitability and balance-sheet concerns that could magnify risks from the Kashiv deal and any financing.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.270-0.270 for the period, compared to the consensus EPS estimate of 0.160. The company issued revenue guidance of $723.0 million-$723.0 million, compared to the consensus revenue estimate of $715.0 million. Amneal Pharmaceuticals also updated its FY 2026 guidance to 0.950-1.050 EPS.

Analyst Ratings Changes

A number of research firms recently issued reports on AMRX. UBS Group began coverage on shares of Amneal Pharmaceuticals in a report on Friday. They set a "buy" rating and a $19.00 price objective for the company. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Zacks Research downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.00.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $13.02 on Wednesday. The company has a market capitalization of $4.10 billion, a PE ratio of 56.61 and a beta of 1.32. Amneal Pharmaceuticals has a 52-week low of $7.02 and a 52-week high of $15.42. The company has a 50-day simple moving average of $13.17 and a 200 day simple moving average of $12.53.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Wednesday, April 22nd. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.11. Amneal Pharmaceuticals had a net margin of 2.39% and a negative return on equity of 228.24%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. As a group, analysts forecast that Amneal Pharmaceuticals will post 0.9 EPS for the current fiscal year.

More Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q1 results and near-term guidance beat expectations: Amneal reported Q1 EPS of $0.26 vs. the $0.15 consensus and provided Q1 EPS guidance of $0.270 (above the $0.160 consensus) and revenue guidance of $723M vs. $715M consensus — evidence of stronger-than-expected core performance. AMRX Marketbeat earnings summary
• Positive Sentiment: Raised FY2026 outlook: Amneal set FY2026 EPS guidance of $0.95–1.05 (vs. $0.95 consensus) and revenue guidance of $3.1B–$3.2B, signaling management expects continued top-line growth for the year. GlobeNewswire release on acquisition and guidance
• Positive Sentiment: Acquisition to build biosimilars scale: Amneal agreed to acquire Kashiv BioSciences for up to $1.1B (cash + stock) to expand biologics development and manufacturing capabilities and target a large loss-of-exclusivity market — a strategic move to diversify into higher-margin complex therapies. The deal requires shareholder and regulatory approvals and is expected to close in H2 2026. Reuters: Amneal to buy Kashiv BioSciences
• Neutral Sentiment: Positive clinical news for Crexont supports product growth thesis: Interim Phase 4 ELEVATE‑PD data show meaningful increases in “good on” time for Crexont in Parkinson’s patients, supporting commercial upside for key specialty products. Business Insider: Crexont Phase 4 results
• Negative Sentiment: Profitability and capital structure remain concerns: despite the beat, Amneal’s reported net margin is low (~2.4%) and return on equity is deeply negative (−228%), highlighting ongoing profitability and balance-sheet issues that could amplify market sensitivity to the Kashiv deal and any financing/dilution. AMRX Marketbeat financials

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Westshore Wealth LLC bought a new position in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $13,833,000. Morgan Stanley boosted its position in shares of Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company's stock valued at $60,708,000 after acquiring an additional 1,315,018 shares during the period. Rubric Capital Management LP boosted its position in shares of Amneal Pharmaceuticals by 9.1% in the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock valued at $94,737,000 after acquiring an additional 974,355 shares during the period. Norges Bank bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $11,208,000. Finally, New York State Common Retirement Fund boosted its position in shares of Amneal Pharmaceuticals by 281.3% in the fourth quarter. New York State Common Retirement Fund now owns 841,193 shares of the company's stock valued at $10,599,000 after acquiring an additional 620,566 shares during the period. Institutional investors own 31.82% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.